Adoke Yeka
ID: UNCST-2021-R004300
|
Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 plus Pyronaridine Administered once Daily for 1 or 2 Days to Adults and Adolescents with Acute Uncomplicated Plasmodium falciparum Malaria
REFNo: HS2736ES
To evaluate the safety and
tolerability of the M5717-
pyronaridine combination in
adult participants with acute
uncomplicated malaria due to
P. falciparum.
Secondary.
o describe the clinical efficacy
of the M5717-pyronaridine
combination in adult participants
with acute uncomplicated
malaria due to P. falciparum
|
Tororo, Central
|
Uganda |
2023-03-16 12:35:56 |
2026-03-16 |
200 |
Participants Are ≥ 12 and ≤ 55 years of age (≥ 18 and ≤ 55 years of age for
Part A) at the time of signing the informed consent.
Type of Participant
and Disease
Characteristics:
2. Microscopic confirmation of acute uncomplicated
P. falciparum using Giemsa-stained thick and thin film.
3. P. falciparum parasitemia of ≥ 1,000 to ≤ 50,000 asexual
parasites/µL of blood in Part A and P. falciparum parasitemia
of > 1,000 to ≤ 150,000 asexual parasites/µL of blood in Part B.
4. Axillary temperature ≥ 37.5ºC or tympanic temperature
≥ 38.0ºC (use as per COVID-19 protocols at the site [only at
Screening]), or history of fever during the previous 24 hours (at
least documented verbally).
Weight: 5. Have a body weight ≥ 24 kg |
Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA, Darmstadt, Germany Frankfurter Str. 250 64293, Darmstadt, Germany |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants.
REFNo: HS2646ES
The primary objective of this study is to confirm the dose of ATV/co or DRV/co in HIV-1 infected pediatric participants, to confirm the dose of F/TAF in HIV-1 infected pediatric participants and to evaluate the safety and tolerability these medications.
|
Mityana, Mityana
Mubende, Mubende
Masaka, Masaka
Rakai, Kalisizo
Kampala, Kampala
Wakiso, Entebbe
|
Uganda |
2023-03-09 23:33:04 |
2026-03-09 |
15 |
The study will be conducted in young children and adolescents aged 3 to < 18 years; HIV-1 infected on a stable antiretroviral regimen for a minimum of 3 months. In Uganda, the study will be conducted by researchers from the coordinating site, MU-JHU Research Collaboration, MU-JHU CARE – Kampala, Uganda, in collaboration with Africa Medical and Behavioral Sciences Organization (AMBSO) – Kampala and SICRA-TASO MULAGO National Referral Hospital, Masaka, Uganda. |
Gilead Sciences Inc |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Raymond Tweheyo
ID: UNCST-2020-R014507
|
Understanding the effect of varied financial compensation structure for improving the performance, motivation and retention of Community Health Workers in Uganda - a quasi experiment
REFNo: HS2689ES
General objective: To understand the effect of varied financial compensation structure for improving the performance, motivation and retention of Community Health Workers in Uganda.
Specific objectives:
1. To determine the optimal performance based financial incentive incentive's structure required for improving the performance, motivation and retention of CHWs.
2. To explore the acceptability and perceptions of potential sustainability of CHWs financial compensation structure to various stakeholders, including the CHWs, and the CHW supervisors at the district and Ministry of Health.
3. To explore the perceived value and impact of financial incentives on CHW's job satisfaction, personal income and livelihood.
|
Wakiso, all parishes
Mpigi, all parishes
Mbale, all parishes
Jinja, all parishes
|
UK |
2023-03-07 10:40:31 |
2026-03-07 |
3,215 children under five, 720 Community Health Workers, 32 Key Informants |
1. Women of reproductive age (18 to 49 years) who have a child under five years of age.
2. Community Health Workers (18 years and above)
3. Adult Key Informants - district, Ministry of Health and Implementing Partner officials |
USAID/ Living Goods |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Rachel Brathwaite
ID:
|
Assessing the Feasibility of Economic Approaches to Prevention of Substance
Abuse among Adolescents
REFNo: HS2683ES
Aim 1. Examine the prevalence and consequences of ADU in a cohort of 200 AYLHIV (ages 18-24) seen at six (6) HIV clinics in southwestern Uganda.
Aim 2. Using a mixed methods approach, identify the multi-level (individual, interpersonal, community and structural) factors associated with ADU among AYLHIV.
Aim 3. Using a subset of the sample, explore the feasibility and short-term effects of a family-based economic empowerment intervention on ADU among AYLHIV.
|
Masaka,
|
Trinidad and Tobago |
2023-03-02 15:32:31 |
2026-03-02 |
230 |
220 Adolescents and youths living with HIV aged 18-24 years. 10 healthcare providers aged >18 years. |
National Institute on Alcohol Abuse and Alcoholism |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Harriet Mayanja-Kizza
ID: UNCST-2021-R013074
|
PHASE 2C CLINICAL TRIAL OF NOVEL, SHORT-COURSE REGIMENS FOR THE TREATMENT OF PULMONARY TUBERCULOSIS:
CRUSH-TB (Combination Regimens for Shortening TB Treatment)
REFNo: HS2650ES
Primary objective
(1) To compare the efficacy of each experimental regimen to the efficacy of standard treatment, using the intermediate endpoint of time to culture negative in liquid media.
Secondary objectives
(1) To compare the proportion of participants with a grade 3 or higher adverse event in each experimental arm with the control arm
(2) To describe the proportion of participants experiencing lack of sustained cure during treatment or follow-up to 52 weeks in each experimental arm as compared to control and make predictions as to how these regimens would perform in future phase III trials.
(3) To compare the efficacy of each experimental regimen to the efficacy of standard treatment, using the intermediate endpoint of time to culture negative in solid media
(4) To compare the proportion of participants in each arm who convert liquid and solid sputum cultures to negative by (a) 8 weeks of treatment and (b) 12 weeks of treatment
(5) To describe the rate of all-cause study drug discontinuation in each arm
(6) To compare time to sputum culture positivity curves through 17 weeks in the Mycobacterial Growth Indicator Tube (Bactec MGIT960) across arms
(7) To describe the proportion of participants experiencing lack of sustained cure during treatment or follow-up up to 78 weeks in each experimental arm as compared to control and make predictions as to how these regimens would perform in future phase III trials.
(8) To describe the population PK of bedaquiline and its M2 metabolite, with or without rifabutin co-administration (PK#1)
(9) To conduct pharmacokinetic/pharmacodynamics study of the test drugs to determine relationships between pharmacokinetic parameters (AUC, Cmax) and outcome measures (time to culture negativity or rate of change in TTP) using non-linear mixed effects models, adjusting for key covariates that may affect outcomes (e.g. companion drugs, HIV status, cavitary disease) (PK#2)
|
Kampala, Mulago
|
Uganda |
2023-02-21 13:13:53 |
2026-02-21 |
288 overall, 100 in Uganda |
This will be a multisite international study. Male and female participants who are age 12 or older and have suspected or proven pulmonary tuberculosis will be enrolled into the study.
Enrollment will be open to all TBTC sites willing to participate and who have completed trial start-up requirements.
Target enrollment is at least 288 participants (96 participants per arm).
Pregnant or breast-feeding individuals will be excluded from the study because of uncertainties about the safety of bedaquiline, delamanid, and moxifloxacin in these groups. The sex, ethnicity, and socioeconomic background of study participants are expected to mirror those of the populations served by local tuberculosis clinics and the populations most affected by tuberculosis worldwide.
Co-enrollment in other therapeutic clinical trials is not allowed.
|
U.S. Centers for Disease Control and Prevention |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Wietse Tol
ID: UNCST-2021-R013085
|
AlCohol use in HumanitariAN settings: a programme of work to address alcohol use disorders and associated adversities among conflict-affected populations in UGanda and UkrainE (CHANGE)
REFNo: SS1596ES
• To identify strategies and techniques from evidence-based alcohol use therapies which can be integrated into PM+, and to develop a new intervention called PM+A (Problem Management Plus Alcohol)
• To adapt PM+A to local circumstances, and to examine the feasibility, acceptability, perceived effectiveness, and preliminary impact of PM+A
• To evaluate effectiveness and cost-effectiveness of PM+A through two single-blind randomised controlled trials in Uganda and Ukraine
• To explore the process of implementation, and to identify, characterise and explain mechanisms that promote or inhibit the delivery and take-up of PM+A in both settings
• To examine the potential for scaling-up PM+A in Uganda and Ukraine
|
Arua, Ofua zone Rhino Camp
|
Netherlands |
2023-02-17 12:18:30 |
2026-02-17 |
60 |
Adult South Sudanese men (>18 years) who meet all the following criteria.;
Alcohol Use Disorder Identification Test (AUDIT) score 8-19 (Saunders et al., 1993)
2) Elevated levels of psychological distress (Kessler Psychological Distress Scale (ten item version) (K10 >6) (Kessler et al., 2002)
|
Wellcome Trust and the Department of Health and Social Care, through the National Institute for Health Research |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
.jpg)
|
Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. Version 1.0, 22 September 2022. DAIDS study protocol ID: 38932
REFNo: HS2599ES
iii. Cohort 2: To describe the maintenance of viral suppression and immunologic activity of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),iv. Cohort 2: To describe HIV-1 genotypes and phenotypes for children who experience virologic failure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CAB LA + RPV LA (injectable only),ii. Cohort Cohort 2: To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),i. Cohort 2: To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable) and 44 weeks of CAB LA + RPV LA (injectable only),ii Cohort 1: To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oral and injectable) through Week 24,i.Cohort 1: To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable) through Week 24,
|
Kampala, all parishes
Wakiso, all parishes
|
Uganda |
2023-02-13 11:10:13 |
2026-02-13 |
90 children and 90 parents/ caregivers worldwide but MUJHU plans to enroll 5 -15 children and 5-15 parents/ caregivers. |
Children living with HIV-1, two years to less than 12 years of age
and weighing ≥10 kg and <40 kg, who are virologically suppressed on
stable antiretroviral therapy and their parents/caregivers.
|
DAIDS/NIH |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES
Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
|
Mbarara, Kamukuzi
Mbarara, Kakoba
|
Uganda |
2023-02-09 11:06:56 |
2026-02-09 |
324 |
15 years and above, female and male wo are on TLD irrespective of tribe |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
|
A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and
antiviral effect of S-217622 compared with placebo in non-hospitalized participants with
COVID-19
REFNo: HS2642ES
The main intent of the study is to evaluate the efficacy of S-217622 vs. placebo. The study will be conducted in the setting of the locally available standard-of-care COVID-19 treatment. High-risk and low-risk participants will be analyzed together for the primary analysis and separately for secondary analyses. The following primary, secondary, and exploratory objectives will be addressed in the modified intent-to-treat (mITT) population, except for the safety analyses, which will be analyzed in the Safety population, and pharmacokinetic (PK) analyses, which will be analyzed in the PK population.
|
Tororo, All Parishes
|
Uganda |
2023-02-06 17:17:04 |
2026-02-06 |
Each site in Uganda will (through competitive enrolment) enroll at least 8 participants making a total of 32 participants for all Uganda sites. |
Outpatient adults (≥18 years) with: a) documented positive
SARS-CoV-2 nucleic acid or antigen test from a sample
collected ≤120 hours (5 days) prior to randomization, b) onset
of symptoms of COVID-19 ≤5 days prior to randomization,
c) presence of 1 or more select COVID-19 symptoms within
24 hours prior to randomization. Participants will be eligible
regardless of vaccination status and will be classified as either
high risk or low risk.
High-risk participants: defined as aged ≥65 years or those with
presence of high-risk conditions.
|
National Institute of Allergy and Infectious Diseases (NIH), Division of AIDS (DAIDS) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Noella Okalany Akwi Regina
ID: UNCST-2022-R011085
|
Congenital Cytomegalovirus Infection in Eastern Uganda
REFNo: HS2668ES
To determine the short-term neurodevelopmental outcomes and hearing impairment associated with congenital cytomegalovirus among infants in Eastern Uganda.,To determine the incidence of, and risk factors for postnatally acquired cytomegalovirus among infants in Eastern Uganda.,To describe the factors associated with congenital cytomegalovirus infection in neonates in Eastern Uganda.,To determine the prevalence of congenital cytomegalovirus infection among neonates in Eastern Uganda,To investigate the burden of congenital cytomegalovirus and its outcomes among infants in Eastern Uganda.,
|
Mbale, Mbale
Budaka, Budaka
|
Uganda |
2023-02-06 16:21:08 |
2026-02-06 |
2000 |
0 - 6 months of age |
University of Liverpool |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Kathy Burgoine
ID: UNCST-2022-R011521
|
Impact of prophylactic Continuous Positive Airway Pressure in the Delivery Room (DR-CPAP) on neonates <1500g in a low-resource setting: A feasibility trial
REFNo: HS2605ES
- To determine the acceptability of DR-CPAP to healthcare workers in a low-resource setting
- To determine the post-intervention acceptability of using a two-stage consent process in neonatal emergencies in the delivery room in this setting
- To evaluate the feasibility of a third-party allocation process for randomisation by determining the time to randomization
- To evaluate feasibility of initiating DR-CPAP in a low-resource setting in infants with birthweight 800-1500g within 15 minutes of delivery
- To determine the safety of initiating DR-CPAP in a low-resource setting
- To estimate the sample size to be used for future evaluation in the full trial
- To assess the feasibility of secondary outcome measures to be used in the full trial
|
Mbale,
|
UK |
2023-02-02 12:18:23 |
2026-02-02 |
100 |
The study population will be inborn preterm infants with a birthweight of 800g to less than 1500g who are spontaneously breathing at 5 minutes of life. They will be recruited within 15 minutes of birth and followed up until death or 28 days. Both male and female infants will be included. |
Mbale Clinical Research Institute (MCRI) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Yerusa Kiirya
ID:
|
Acceptability, Feasibility and Effectiveness of a WhatsApp peer support group as a strategy to improve antiretroviral therapy adherence among youth in Kampala District
REFNo: SIR170ES
To determine the effectiveness of a WhatsApp peer support group combined with the standard of care in improving ART adherence among YLHIVA aged 15-24 years in Kampala district.,To determine the effect of a WhatsApp peer support group combined with the standard of care on psychosocial barriers to ART adherence and retention in care among YLHIVA aged 15-24 years in Kampala district.,To assess the feasibility of using a WhatsApp peer support group combined with the standard of care as an ART adherence and retention in care strategy among YLHIVA aged 15-24 years, To asses the acceptability of a WhatsApp peer support group combined with the standard of care as an ART adherence and retention in care strategy among YLHIVA aged 15-24 in Kampala district.,To assess the acceptability, feasibility and effectiveness of a WhatsApp peer support group combined with current standard care as a strategy to improve ART adherence among YLHIVA in Kampala.,
|
Kampala, Kiswa
Kampala, Komambogo
Kampala, Kawala
|
Uganda |
2023-01-20 14:23:51 |
2026-01-20 |
488 |
This study will be conducted among YLHIVA aged 15-24 years currently receiving ART services at
Kiswa, Komambogo and Kawala HCIII with an
ART adherence score of less than 95% within the past 12 months |
Strengthening behavioral and social science research capacity to address evolving challenges in HIV care and prevention in Uganda. |
Engineering and Technology |
Clinical Trial |
Degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (GRAIL) – “Promoting Treatment as Prevention”
REFNo: HS2622ES
2. To assess the impact of gabapentin compared to placebo on: a) alcohol consumption; b) pain severity; c) ART adherence; and d) engagement in HIV care, in order to explore potential mechanisms by which gabapentin may lead to HVL suppression.,1. To test the efficacy of gabapentin versus placebo to achieve undetectable HVL (Primary Outcome at 3 months; Secondary Outcome at 6 & 12 months),
|
Mbarara, Kamukuzi
Mbarara, Kakoba
|
Uganda |
2023-01-18 18:33:54 |
2026-01-18 |
300 |
18 years and above, female and male, irrespective of tribe, who are on antiretroviral therapy with detectable viral load and are unhealthy alcohol consumers. |
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
Evaluation of the performance of novel molecular point of care diagnostics for SARS-CoV-2
REFNo: HS2588ES
To assess the ease of use of the molecular POC devices being evaluated using a System Usability Scale (SUS) questionnaire administered to platform’s operators (minimum 3, where possible)., To evaluate the diagnostic accuracy of such platforms in detecting SARS-CoV-2 on respiratory specimens, compared with reference standard RTPCR in specific subgroups defined based on disease stage (days since symptoms onset), RTPCR Ct values (as surrogate for viral load). Participant’s vaccination status, previous COVID-19 infection(s) and SARS-CoV-2 genetic variant causing participant’s infection, determined by sequencing of the viral genome, may also be considered as subgroups. , To evaluate the diagnostic accuracy of molecular POC devices in detecting SARS-CoV-2 on respiratory specimens, compared with reference standard RT-PCR (WHO EUL or FDA EUA approved), among COVID-19 symptomatic individuals,
|
Kampala, Mulago
Kampala, Kiruddu
Kampala, Kawempe
Kampala, Butabika
|
Uganda |
2023-01-18 18:21:06 |
2026-01-18 |
200 |
The study will focus on adults with symptoms compatible with COVID-19 (and/or specimens collected from them) attending healthcare facilities in Uganda.
If a participant is screened and enrolled but is not able to provide the specimens required for the study, this participant will be withdrawn. |
FIND GENEVA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Raymond Tweheyo
ID: UNCST-2020-R014507
|
Evaluating the pilot of the Community Health Extension Worker (CHEW) strategy in Uganda: assessing feasibility, and effectiveness for improving Village Health Team (VHT) supervision and reporting
REFNo: HS2545ES
General Objective
To explore the acceptability, document the implementation process and evaluate the effectiveness of the Community Health Extension Worker strategy in two districts of Uganda to guide improving the community health system
Specific Objectives
1) To assess the acceptability of introducing a Community Health Extension Worker (CHEW) strategy in a district health system.
2)To document the process of setting up and implementing a Community Health Extension
Worker (CHEW) strategy within a district health system.
3) To estimate the program costs and duration for setting up a government-led Community Health Extension Worker (CHEW) strategy within a district health system.
4) To determine the effectiveness of the CHEW strategy for improving the quality of Village Health Team (VHT) member’s supervision and reporting in a district health system.
5) To assess the effect of the CHEW strategy on community-level indicators: completion of four antenatal care visits, skilled delivery attendance, fully immunized under-fives, and U5 sick children seen by VHTs and treated within 24 hours.
|
Mayuge, all parishes
Lira, all parishes
Kabarole, all parishes
Kyotera, all parishes
|
UK |
2023-01-03 13:08:01 |
2026-01-03 |
3,016 women of reproductive age |
1) Household members: Adult women of reproductive age 18 to 49 years.
2) Community health workers - 18 years and above
3) Health facility workers - 18 years and above
4) District technical and political leaders - 18 years and above
5) Community Health Implementing partners - adults, 18 years and above |
USAID/ Uganda Health Systems Strengthening Activity (UHSS) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pontiano Kaleebu
ID: UNCST-2020-R019901
|
Performance evaluation of the Determine™ HIV Early Detect 4th Generation HIV Rapid Diagnostic test
REFNo: HS2603ES
Primary Objectives:
1. To evaluate the Laboratory performance (Sensitivity and specificity) of the Determine™ HIV Early Detect
2. To assess the field performance of the Determine™ HIV Early Detect in parallel with the Determine™ HIV-1/2 test
Secondary Objective:
1. To assess the effectiveness of the Determine Early Detect to identify acute HIV infection among newly infected individuals
|
Buikwe, kawolo
Kampala, Kisenyi
Kampala, Naguru
Mityana, Mityana
Mukono, Mukono hospital
Wakiso, Wagagai
Wakiso, UVRI
Kayunga, Kayunga hospital
Kalungu, Nkozi hospital
Gomba, Gombe hospital
|
Uganda |
2022-12-23 18:06:59 |
2025-12-23 |
10,000 |
The study will enroll;
- Adults above 18 years of age
- Willing to have an HIV test.
- Eligible for testing as per the National HTS eligibility screening tool
- Documented
|
- Abott Diagnostics |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Lawrence Okello Rafaih
ID:
|
Evaluation practices and strategy performance of local NGOs in Uganda
REFNo: SS1561ES
4. To determine the relationship between organizational evaluation steering process and strategy performance of NGOs in Uganda,3. To establish the relationship between organizational evaluation technical expertise and strategy performance of NGOs in Uganda,2. To determine the relationship between evaluation planning process and strategy performance of NGOs in Uganda,1. To validate the contextual relevance of organizational effectiveness competency model for strategy evaluation of NGOs in Uganda.,The purpose of this study is to validate the extent to which evaluation practices influence strategy performance of national NGOs in Uganda.,
|
Moroto, Moroto
Gulu, Gulu
Kampala, Kampala
Mbarara, Mbarara
Moroto, Moroto
Gulu, Gulu
Kampala, Kampala
Mbarara, Mbarara
Lira, Lira
|
Uganda |
2022-12-19 12:19:45 |
2025-12-19 |
379 |
In short study targets adult population ( aged between 18-70 years)population from local NGOs who are members of the national NGO forums spread across the country. A total of 40 cluster NGO forums will be engaged to reach our to gather a proportionate sample of about 80 respondents per region. Similarly, Only adult respondents will be included for key informant interviews |
Lawrence Rafaih Okello |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Daniella Ferguson
ID:
|
A Retrospective Analysis of Suramin Treatment forStage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT) in Uganda and Malawi
REFNo: HS2582ES
Primary objectives
The primary objective is to determine whether standard of care treatment with suramin, as currently practiced in Uganda and Malawi, leads to better health outcomes in patients with S1 TBR HAT than observed in an untreated natural history cohort with source data from a published epidemiologic study.
Secondary objectives
The secondary objective is to evaluatethe safety and tolerability of suramin.
|
Kaberamaido, Lwala
|
South Africa |
2022-12-19 12:17:26 |
2025-12-19 |
150 -200 patients |
The study will include TBR HAT patients treated with suramin between 2000 and 2020 in Uganda and Malawi. The study will include all of the approximately 150 - 250 patients evaluated through chart review who are deemed eligible and have sufficient data. A natural history cohort composed of source data from approximately 200 patients from a published epidemiological study will be used as a comparator. |
PaxMedica, Inc. 303 South Broadway Suite 125 Tarrytown, NY |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
KENNETH MUGABE
ID: UNCST-2022-R010732
|
Using lactate testing to improve maternal sepsis identification: a multi-country test accuracy study: LACTate in mATernal sEpsis
REFNo: HS2589ES
VI. Conduct a validation study of an alternative reference standard in which the SOFA score is modified to incorporate maternity specific ranges for creatinine and platelet concentration.,V. Exploratory analysis will examine the effect of adjusting the threshold values for both vital sign and lactate assessment on the sensitivity and specificity of the index tests.,IV. To explore if the test accuracy of lactate in addition to maternal vital sign monitoring alone varies by the pre-specified subgroups of pregnancy status (pregnant or post-delivery (including abortion or miscarriage)) and recruitment country.,III. To explore if baseline venous lactate, in addition to vital sign measurements, improves prediction of severe morbidity and mortality from infection.,II. To assess short-term predictive value of lactate testing, by comparing the baseline index test with 24-hour reference standard, in those without sepsis at baseline.,I. Immediate diagnostic value of lactate testing by comparing the baseline index test with baseline reference standard.,Determine the diagnostic accuracy of maternal venous lactate measurement in addition to maternal vital sign thresholds, in maternal sepsis in low-resource health facility settings in Malawi, Uganda and Pakistan.,
|
|
Uganda |
2022-12-12 15:55:39 |
2025-12-12 |
500 (150 in Uganda) |
Women, 16years or greater, with suspected infections, who are pregnant or recently pregnant(up to 42 days) |
University of Liverpool |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF HERBAL PRODUCTS FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS INCLUDING SARS-COV2 IN UGANDA; PHASE 2A OPEN LABEL CLINICAL TRIAL
REFNo: HS2548ES
The general objective is to assess the safety, pharmacokinetics and preliminary efficacy of TazCoV and Vidicine for the treatment of acute respiratory viral infections (SARS-CoV2, RSV and Influenza A/B) in Uganda.
Specific objectives
1. To determine the safety and pharmacokinetics of TAZCOV and Vidicine herbal products among adult patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza A/B
2. To determine the extent of SARS-CoV2, RSV and Influenza A/B viral clearance among adult patients with acute viral respiratory infection treated using TAZCOV and Vidicine
3. To establish time-to-remission of symptoms among patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine
4. To evaluate disease progression among patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine
|
Kampala, Mulago
|
Uganda |
2022-11-29 12:38:24 |
2025-11-29 |
510 |
The maximum individual participant trial duration will be 90. The actual time the trial will last will depend on the rate of enrollment. It is estimated that the trial will take 18 months. days. |
The Government of Uganda through the Ministry of Science, Technology and Innovation-Office of the President (STI-OP) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
| View |
|
Sort By: |
|
|
|
| |
|
